Identification of the heparin-binding domains of the interferon-induced protein kinase, PKR

FEBS Journal

Volumn 272, Issue 6, 2005, Pages 1425-1439

  Fasciano, Stephen ^a   Hutchins, Brian ^a   Handy, Indhira ^a   Patel, Rekha C ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Domain mapping; dsRNA; Heparin; Interferon; Protein kinase

Indexed keywords

ANTIVIRUS AGENT; HEPARIN; INITIATION FACTOR 2ALPHA; INTERFERON; PROTEIN KINASE R;

ARTICLE; AUTOPHOSPHORYLATION; BINDING KINETICS; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; BINDING SITES; CONSENSUS SEQUENCE; DNA PRIMERS; EIF-2 KINASE; HEPARIN; HUMANS; INTERFERONS; KINETICS; MUTAGENESIS; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; SEQUENCE DELETION; TRANSCRIPTION, GENETIC;

EID: 15944409863     PISSN: 1742464X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2005.04575.x     Document Type: Article

References (65)

1. de Veer MJ, Holko M, Frevel M, Der Walker ES, Paranjape JM, Silverman RH & Williams BR (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69, 912-920.
2. Sen GC & Ransohoff RM (1993) Interferon-induced antiviral actions and their regulation. Adv Virus Res 42, 57-102.
3. Clemens MJ (1997) PKR - a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol 29, 945-949.
4. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR & Hovanessian AG (1990) Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62, 379-390.
5. Hovanessian AG & Galabru J (1987) The double-stranded RNA-dependent protein kinase is also activated by heparin. Eur J Biochem 167, 467-473.
6. Patel RC & Sen GC (1998) PACT, a protein activator of the interferon-induced protein kinase, PKR. Embo J 17, 4379-4390.
7. Ito T, Yang M & May WS (1999) RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem 274, 15427-15432.
8. Patel CV, Handy I, Goldsmith T & Patel RC (2000) PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR. J Biol Chem 275, 37993-37998.
9. Colthurst DR, Campbell DG & Proud CG (1987) Structure and regulation of eukaryotic initiation factor eIF-2. Sequence of the site in the alpha subunit phosphorylated by the haem-controlled represser and by the double-stranded RNA-activated inhibitor. Eur J Biochem 166, 357-363.
10. Samuel CE (1993) The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans. J Biol Chem 268, 7603-7606.
11. Jagus R, Joshi B & Barber GN (1999) PKR, apoptosis and cancer. Int J Biochem Cell Biol 31, 123-138.
12. Williams BR (1999) PKR; a sentinel kinase for cellular stress. Oncogene 18, 6112-6120.
13. Koromilas AE, Roy S, Barber GN, Katze MG & Sonenberg N (1992) Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 257, 1685-1689.
14. Meurs EF, Galabru J, Barber GN, Katze MG & Hovanessian AG (1993) Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90, 232-236.
15. Williams BR (2001) Signal integration via PKR. Sci STKE 2001, RE2.
16. Judware R & Petryshyn R (1991) Partial characterization of a cellular factor that regulates the double-stranded RNA-dependent eIF-2 alpha kinase in 3T3-F442A fibroblasts. Mol Cell Biol 11, 3259-3267.
17. Salzberg S, Mandelbaum M, Zalcberg M & Shainberg A (1995) Interruption of myogenesis by transforming growth factor beta 1 or EGTA inhibits expression and activity of the myogenic-associated (2′-5′) oligoadenylate synthetase and PKR. Exp Cell Res 219, 223-232.
18. Katze MG, Wambach M, Wong ML, Garfinkel M, Meurs E, Chong K, Williams BR, Hovanessian AG & Barber GN (1991) Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated, 68,000-Mr protein kinase in a cell-free system. Mol Cell Biol 11, 5497-5505.
19. Patel RC & Sen GC (1992) Identification of the double-stranded RNA-binding domain of the human interferon-inducible protein kinase. J Biol Chem 267, 7671-7676.
20. Green SR & Mathews MB (1992) Two RNA-binding motifs in the double-stranded RNA-activated protein kinase, DAI. Genes Dev 6, 2478-2490.
21. McCormack SJ, Thomis DC & Samuel CE (1992) Mechanism of interferon action: identification of a RNA binding domain within the N-terminal region of the human RNA-dependent P1/eIF-2 alpha protein kinase. Virology 188, 47-56.
22. Nanduri S, Carpick BW, Yang Y, Williams BR & Qin J (1998) Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. Embo J 17, 5458-5465.
23. Patel RC, Stanton P & Sen GC (1994) Role of the amino-terminal residues of the interferon-induced protein kinase in its activation by double-stranded RNA and heparin. J Biol Chem 269, 18593-18598.
24. Romano PR, Green SR, Barber GN, Mathews MB & Hennebusch AG (1995) Structural requirements for double-stranded RNA binding, dimerization, and activation of the human eIF2a kinase DAI in Saccharomyces cerevisiae. Mol Cell Biol 15, 365-378.
25. Schmedt C, Green SR, Manche L, Taylor DR, Ma Y & Mathews MB (1995) Functional characterization of the RNA-binding domain and motif of the double-stranded RNA-dependent protein kinase DAI (PKR). J Mol Biol 249, 29-44.
26. St Johnston D, Brown NH, Gall JG & Jantsch M (1992) A conserved double-stranded RNA-binding domain. Proc Natl Acad Sci USA 89, 10979-10983.
27. Fierro-Monti I & Mathews MB (2000) Proteins binding to duplexed RNA: one motif, multiple functions. Trends Biochem Sci 25, 241-246.
28. Carpick BW, Graziano V, Schneider D, Maitra RK, Lee X & Williams BR (1997) Characterization of the solution complex between the interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans-activating region RNA. J Biol Chem 272, 9510-9516.
29. Nanduri S, Rahman F, Williams BR & Qin J (2000) A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR. Embo J 19, 5567-5574.
30. Romano PR, Zhang F, Tan SL, Garcia-Barrio MT, Katze MG, Dever TE & Hinnebusch AG (1998) Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol Cell Biol 18, 7304-7316.
31. Taylor DR, Lee SB, Romano PR, Marshak DR, Hinnebusch AG, Esteban M & Mathews MB (1996) Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR. Mol Cell Biol 16, 6295-6302.
32. Zhang F, Romano PR, Nagamura-Inoue T, Tian B, Dever TE, Mathews MB, Ozato K & Hinnebusch AG (2001) Binding of double-stranded RNA to protein kinase PKR is required for dimerization and promotes critical autophosphorylation events in the activation loop. J Biol Chem 276, 24946-24958.
33. Patel RC, Stanton P, McMillan NM, Williams BR & Sen GC (1995) The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo. Proc Natl Acad Sci USA 92, 8283-8287.
34. Cosentino GP, Venkatesan S, Serluca FC, Green SR, Mathews MB & Sonenberg N (1995) Double-stranded-RNA-dependent protein kinase and TAR RNA-binding protein form homo- and heterodimers in vivo. Proc Natl Acad Sci USA 92, 9445-9449.
35. Wu S & Kaufman RJ (1996) Double-stranded (ds) RNA binding and not dimerization correlates with the activation of the dsRNA-dependent protein kinase (PKR). J Biol Chem 271, 1756-1763.
36. Patel RC & Sen GC (1998) Requirement of PKR dimerization mediated by specific hydrophobic residues for its activation by double-stranded RNA and its antigrowth effects in yeast. Mol Cell Biol 18, 7009-7019.
37. George CX, Thomis DC, McCormack SJ, Svahn CM & Samuel CE (1996) Characterization of the heparin-mediated activation of PKR, the interferon-inducible RNA-dependent protein kinase. Virology 221, 180-188.
38. Patel RC, Handy I & Patel CV (2002) Contribution of double-stranded RNA-activated protein kinase toward antiproliferative actions of heparin on vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 22, 1439-1444.
39. Castellot JJ Jr, Addonizio ML, Rosenberg R & Karnovsky MJ (1981) Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol 90, 372-379.
40. Clowes AW & Karnowsky MJ (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265, 625-626.
41. Kleiman NS, Weitz JI, Campbell GR, Campbell JH, Woods TC, Blystone CR, Yoo J, Edelman ER, Cassady KA & Gross M (2000) Putting heparin into perspective: its history and the evolution of its use during percutaneous coronary interventions. J Invasive Cardiol 12, 20F-26.
42. Young JJ, Kereiakes DJ & Grines CL (2000) Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National investigators collaborating on enoxaparin investigators. J Invasive Cardiol 12, E14-E18; discussion E25-18.
43. Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809.
44. Cardin AD & Weintraub HJ (1989) Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9, 21-32.
45. Patel RC, Stanton P & Sen GC (1996) Specific mutations near the amino terminus of double-stranded RNA-dependent protein kinase (PKR) differentially affect its double-stranded RNA binding and dimerization properties. J Biol Chem 271, 25657-25663.
46. Kaufman RJ & Murtha P (1987) Translational control mediated by eucaryotic initiation factor-2 is restricted to specific mRNAs in transfected cells. Mol Cell Biol 7, 1568-1571.
47. Davies MV, Furtado M, Hershey JW, Thimmappaya B & Kaufman RJ (1989) Complementation of adenovirus virus-associated RNA I gene deletion by expression of a mutant eukaryotic translation initiation factor. Proc Natl Acad Sci USA 86, 9163-9167.
48. Park H, Davies MV, Langland JO, Chang HW, Nam YS, Tartaglia J, Paoletti E, Jacobs BL, Kaufman RJ & Venkatesan S (1994) TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci USA 91, 4713-4717.
49. Peters GA, Hartmann R, Qin J & Sen GC (2001) Modular structure of PACT: distinct domains for binding and activating PKR. Mol Cell Biol 21, 1908-.
50. Chong KL, Feng L, Schappert K, Meurs E, Donahue TF, Friesen JD, Hovanessian AG & Williams BR (1992) Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. Embo J 11, 1553-1562.
51. Hanks SK, Quinn AM & Hunter T (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52.
52. Galabru J & Hovanessian A (1987) Autophosphorylation of the protein kinase dependent on double-stranded RNA. J Biol Chem 262, 15538-15544.
53. Tan SL, Gale MJ Jr & Katze MG (1998) Double-stranded RNA-independent dimerization of interferon-induced protein kinase PKR and inhibition of dimerization by the cellular P58IPK inhibitor. Mol Cell Biol 18, 2431-2443.
54. Ortega LG, McCotter MD, Henry GL, McCormack SJ, Thomis DC & Samuel CE (1996) Mechanism of interferon action. Biochemical and genetic evidence for the intermolecular association of the RNA-dependent protein kinase PKR from human cells. Virology 215, 31-39.
55. Hoover RL, Rosenberg R, Haering W & Karnovsky MJ (1980) Inhibition of rat arterial smooth muscle cell proliferation by heparin, II. In vitro studies. Circ Res 47, 578-583.
56. Brieger D & Topol E (1997) Local drug delivery systems and prevention of restenosis. Cardiovasc Res 35, 405-413.
57. Fritze LM, Reilly CF & Rosenberg RD (1985) An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 100, 1041-1049.
58. Ma Y, Henderson HE, Liu MS, Zhang H, Forsythe IJ, Clarke-Lewis I, Hayden MR & Brunzell JD (1994) Mutagenesis in four candidate heparin binding regions (residues 279-282, 291-304, 390-393, and 439-448) and identification of residues affecting heparin binding of human lipoprotein lipase. J Lipid Res 35, 2049-2059.
59. Sendak RA & Bensadoun A (1998) Identification of a heparin-binding domain in the distal carboxyl-terminal region of lipoprotein lipase by site-directed mutagenesis. J Lipid Res 39, 1310-1315.
60. Sendak RA, Berryman DE, Gellman G, Melford K & Bensadoun A (2000) Binding of hepatic lipase to heparin. Identification of specific heparin-binding residues in two distinct positive charge clusters. J Lipid Res 41, 260-268.
61. Thompson LD, Pantoliano MW & Springer BA (1994) Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33, 3831-3840.
62. Jackson RL, Busch SJ & Cardin AD (1991) Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71, 481-539.
63. Margalit H, Fischer N & Ben-Sasson SA (1993) Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J Biol Chem 268, 19228-19231.
64. Lansky Z, Kubala M, Ettrich R, Kuty M, Plasek J, Teisinger J, Schoner W & Amler E (2004) The hydrogen bonds between Arg423 and Glu472 and other key residues, Asp443, Ser477, and Pro489, are responsible for the formation and a different positioning of TNP-ATP and ATP within the nucleotide-binding site of Na(+) /K(+)-ATPase. Biochemistry 43, 8303-8311.
65. Morgan CT, Tsivkovskii R, Kosinsky YA, Efremov RG & Lutsenko S (2004) The distinct functional properties of the nucleotide-binding domain of ATP7B, the human copper-transporting ATPase: analysis of the Wilson disease mutations E1064A, H1069Q, R1151H, and C1104F. J Biol Chem 279, 36363-36371.